VIP Mechanism of Action (Preclinical)
Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide that plays a pivotal regulatory role across neuroendocrine, cardiovascular, and immune signaling networks. Preclinical models demonstrate that VIP activates two primary Class B G-protein coupled receptors, driving intracellular cyclic AMP production and modulating downstream kinase pathways. This technical overview synthesizes current in vitro and animal research regarding VIP receptor binding dynamics, intracellular cascades, and comparative pharmacology.
Quick answer
Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide that plays a pivotal regulatory role across neuroendocrine, cardiovascular, and immune signaling networks. Preclinical models demonstrate that VIP activates two primary Class B G-protein coupled receptors, driving intracellular cyclic AMP production and modulating downstream kinase pathways. This technical overview synthesizes current in vitro and animal research regarding VIP receptor binding dynamics, intracellular cascades, and comparative pharmacology.
Key takeaways
- Vasoactive Intestinal Peptide (VIP) is a basic, 28-residue peptide amide derived from the proteolytic cleavage of the 170-amino-acid precursor prepro-VIP.
- VIP exerts its biological effects primarily through two high-affinity Class B1 G-protein coupled receptors (GPCRs): VPAC1 (VIPR1) and VPAC2 (VIPR2).
- The primary canonical pathway downstream of VPAC1 and VPAC2 stimulation involves coupling to the stimulatory G-protein subunit (Gs alpha).
- In addition to the classical Gs/cAMP/PKA signaling axis, preclinical models demonstrate that VPAC receptor activation can recruit alternative non-canonical signaling pathways depending on cell-type specific receptor density and G-protein stoichiometry.
Structural Biochemistry and Superfamily Classification
Vasoactive Intestinal Peptide (VIP) is a basic, 28-residue peptide amide derived from the proteolytic cleavage of the 170-amino-acid precursor prepro-VIP. First isolated from porcine duodenum, VIP belongs to the secretin/glucagon superfamily of regulatory peptides. Its primary amino acid sequence (H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2) exhibits remarkable evolutionary conservation across vertebrate species, underscoring its essential functional conserved role in cellular signaling.
The secondary structure of VIP is characterized by an N-terminal random coil transition into an amphipathic alpha-helix extending from residue 6 to 28. In vitro nuclear magnetic resonance (NMR) spectroscopy indicates that the amphipathic helical domain is critical for high-affinity receptor recognition, whereas the flexible N-terminus (specifically residues 1–5) is required for receptor activation and signal transduction. Researchers evaluating research peptides within the secretin family often study how hydrophobic interactions along this helical axis mediate receptor docking.
Primary Receptor Targets: VPAC1 and VPAC2 Selectivity
VIP exerts its biological effects primarily through two high-affinity Class B1 G-protein coupled receptors (GPCRs): VPAC1 (VIPR1) and VPAC2 (VIPR2). Both receptors bind VIP with nanomolar affinity (Kd ~ 0.5–2.0 nM). While VPAC1 is constitutively expressed in central nervous system structures, hepatocytes, enterocytes, and T-lymphocytes, VPAC2 expression is highly inducible in immune cells and localized within the suprachiasmatic nucleus, smooth muscle cells, and endocrine pancreas.
Unlike classic ligand-receptor interactions, VIP binding to VPAC1 and VPAC2 involves a two-domain mechanism. The C-terminal helical region of VIP interacts with the extracellular N-terminal domain (ECD) of the receptor, stabilizing the peptide. Subsequently, the N-terminus of VIP inserts into the transmembrane helical bundle, inducing a conformational shift that facilitates intracellular heterotrimeric G-protein coupling. Investigating receptor-selective analogs via wholesale research peptide accounts allows laboratories to map specific tissue responses without cross-receptor activation.
Intracellular Signaling Cascades: Adenylyl Cyclase and cAMP/PKA
The primary canonical pathway downstream of VPAC1 and VPAC2 stimulation involves coupling to the stimulatory G-protein subunit (Gs alpha). Upon ligand binding, the receptor acts as a guanine nucleotide exchange factor (GEF), facilitating the exchange of GDP for GTP on the Gs alpha subunit. The activated Gs alpha subunit dissociates from the beta-gamma complex and stimulates transmembrane adenylyl cyclase (AC) isoforms, predominantly AC2 and AC4.
Adenylyl cyclase catalyzes the conversion of intracellular adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Elevated cAMP levels bind to the regulatory subunits of Protein Kinase A (PKA), releasing active catalytic subunits. PKA subsequently phosphorylates downstream nuclear transcription factors, including the cAMP response element-binding protein (CREB). CREB phosphorylation at Serine-133 promotes recruitment of the coactivator CBP/p300, initiating transcription of target genes involved in cell survival, cytokine modulation, and metabolic homeostasis.
Secondary and Alternative Signaling Vectors: PLC and Calcium Dynamics
In addition to the classical Gs/cAMP/PKA signaling axis, preclinical models demonstrate that VPAC receptor activation can recruit alternative non-canonical signaling pathways depending on cell-type specific receptor density and G-protein stoichiometry. In specific neural and smooth muscle cell assays, VPAC1 couples to Gi/o proteins or Gq/11 proteins, activating Phospholipase C beta (PLC-beta).
Activation of PLC-beta catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses through the cytosol to bind IP3 receptors on the endoplasmic reticulum, triggering a transient influx of intracellular calcium (Ca2+). Simultaneously, DAG and elevated cytosolic Ca2+ activate Protein Kinase C (PKC) isoforms, introducing crosstalk between PKC pathways and Mitogen-Activated Protein Kinase (MAPK/ERK) cascades. Understanding these dual-signaling modalities is critical when designing in vitro functional assays using VIP 2mg research vials.
Immunomodulatory Signaling and Cytokine Suppression Mechanisms
Preclinical research heavily focuses on the potent anti-inflammatory properties of VIP in activated macrophages, dendritic cells, and microglial cultures. In vitro assays demonstrate that VIP suppresses the expression of pro-inflammatory cytokines, including TNF-alpha, IL-6, IL-12, and inducible Nitric Oxide Synthase (iNOS), while upregulating anti-inflammatory mediators such as IL-10.
The molecular mechanism underlying this immunomodulatory effect involves both PKA-dependent and PKA-independent inhibition of the Nuclear Factor Kappa B (NF-kappa-B) pathway. PKA activation phosphorylates p65 subunits or prevents I-kappa-B alpha degradation, thereby blocking NF-kappa-B nuclear translocation. Simultaneously, VIP inhibits the p38 MAPK pathway, destabilizing pro-inflammatory cytokine mRNA transcripts. Laboratory studies investigating neuroinflammation frequently evaluate VIP's microglial activity alongside related neuroprotective agents in specialized animal models.
Vascular and Smooth Muscle Relaxation Pathways
In peripheral vascular and non-vascular smooth muscle tissues, VIP functions as a potent non-adrenergic, non-cholinergic (NANC) inhibitory neurotransmitter. Preclinical isolated organ bath studies show that VIP induces rapid vasodilation and muscle relaxation across pulmonary, coronary, and gastrointestinal preparations.
This relaxation response operates via a dual mechanism. Directly, VIP activates VPAC receptors on vascular smooth muscle cells, elevating cAMP/PKA levels and leading to the phosphorylation of phospholamban and myosin light chain kinase (MLCK) inactivation. Indirectly, VIP acts on endothelial VPAC receptors to stimulate endothelial Nitric Oxide Synthase (eNOS), increasing nitric oxide (NO) generation. NO diffuses into adjacent smooth muscle cells, stimulating soluble guanylyl cyclase (sGC) and cyclic GMP (cGMP) accumulation, reinforcing hyperpolarization via ATP-sensitive potassium (K-ATP) channels.
Comparative Analysis: VIP vs. PACAP-38 and Related Secretin Family Peptides
VIP shares extensive sequence homology and functional overlap with other members of the secretin peptide family. Most notably, Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP-38) exhibits high affinity for both VPAC1 and VPAC2 receptors, identical to VIP. However, PACAP-38 also displays ultra-high affinity for a third receptor, PAC1, which binds VIP with a 100- to 1000-fold lower affinity. Consequently, VIP serves as a selective dual VPAC1/VPAC2 agonist relative to PAC1.
When evaluated alongside gastrointestinal peptides such as Secretin and metabolic regulators such as those explored in GLP-1 receptor research, VIP exhibits distinct pharmacodynamic profiles. Secretin demonstrates preferential binding to the Secretin Receptor (SCTR) over VPAC receptors, whereas VIP lacks activity at the GLP-1 receptor. Comparative matrix assays utilizing these distinct peptides allow researchers to delineate receptor subtype involvement in complex metabolic and neuroendocrine signaling pathways.
In Vitro Degradation and Enzymatic Cleavage Kinetics
A primary consideration in experimental design involving VIP is its short physiological half-life (under 2 minutes in serum). Rapid degradation is mediated by circulating and membrane-bound endopeptidases. Neutral Endopeptidase (NEP / CD10, EC 3.4.24.11) cleaves VIP at specific sites within the core sequence, notably between residues Asp8-Asn9, Ala18-Val19, and Lys20-Lys21, rendering the fragment inactive.
In addition, Dipeptidyl Peptidase IV (DPP-IV / CD26) can cleave the N-terminal His1-Ser2 dipeptide, eliminating the residue critical for GPCR activation while leaving receptor binding capability partially intact. To mitigate rapid degradation in long-term cell culture or tissue bath experiments, investigators often utilize peptidase inhibitors, specific buffer formulations, or non-cleavable synthetic derivatives to ensure stable concentration kinetics throughout the observation window.
Analytical Quality Standards: HPLC/MS and Endotoxin Verification
Because structural fidelity and purity directly impact ligand-receptor binding kinetics and downstream intracellular assays, research reagents must adhere to rigorous analytical standards. PX1 Research synthesizes all VIP lots in USA-based, GMP-compliant facilities operating under strict ISO 17025 laboratory accreditation.
Every batch undergoes comprehensive testing, including High-Performance Liquid Chromatography (HPLC) to verify chemical purity (>98%) and Mass Spectrometry (MS) to confirm exact molecular weight. Crucially, given VIP's extensive application in immune and neuronal cell cultures highly sensitive to pyrogens, PX1 conducts rigorous Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below Industry thresholds (<0.01 EU/μg). For complete transparency, independent third-party Certificates of Analysis (COAs) are available for review via our peptide purity validation guide.
Laboratory Reconstitution and Handling Benchmarks
For optimal stability and reproducible experimental outcomes, lyophilized VIP should be stored at -20°C or -80°C upon receipt, protected from light and moisture. Lyophilized cakes must be allowed to equilibrate to room temperature before reconstitution to prevent condensation from introducing moisture into the vial.
Reconstitution should be performed using sterile, bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4). Gentle swirling is recommended; aggressive vortexing or sonic agitation must be avoided to prevent mechanical shearing of the amphipathic alpha-helical structure. For detailed protocol parameters regarding dissolution solvents and long-term aliquot storage, consult our technical resource on endotoxin testing and peptide preparation.
Frequently Asked Questions
What are the primary receptor targets of VIP in preclinical research?
VIP acts as a high-affinity agonist at two Class B1 G-protein coupled receptors: VPAC1 and VPAC2. Both receptors bind VIP with nanomolar affinity to stimulate intracellular adenylyl cyclase activity.
How does VIP signaling differ from PACAP-38?
While VIP and PACAP-38 bind VPAC1 and VPAC2 with equivalent affinity, PACAP-38 also binds the PAC1 receptor with high affinity. VIP exhibits negligible affinity for PAC1, making it a valuable tool for differentiating PAC1-specific from VPAC1/2-mediated signaling.
What second messenger cascades are activated by the VIP mechanism of action?
The principal pathway activated by VIP is the Gs-protein/adenylyl cyclase cascade, which increases intracellular cyclic AMP (cAMP) and activates Protein Kinase A (PKA). Secondary activation of PLC-beta, leading to IP3/DAG generation and intracellular calcium mobilization, can also occur in specific cell types.
Why is endotoxin testing critical for VIP research reagents?
VIP is frequently studied in immunomodulatory and microglial cell culture models. Bacterial endotoxin (LPS) contamination can falsely stimulate TLR4 pathways, masking or confounding VIP's innate anti-inflammatory and signaling effects. PX1 Research tests all VIP lots to ensure endotoxin levels remain below <0.01 EU/μg.
What analytical methods verify the quality of PX1 Research VIP?
PX1 Research utilizes High-Performance Liquid Chromatography (HPLC) to confirm structural purity (>98%) and Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS) or LC-MS to confirm correct amino acid sequence mass, supported by lot-specific COAs.
How should VIP be reconstituted for in vitro cell culture assays?
VIP should be reconstituted in sterile, endotoxin-free PBS or sterile water under a laminar flow hood. Avoid high-shear vortexing. Reconstituted stock solutions should be aliquoted and stored at -80°C to minimize freeze-thaw degradation.
What enzymes are responsible for VIP degradation in tissue models?
VIP is rapidly inactivated by Neutral Endopeptidase (NEP / CD10) and Dipeptidyl Peptidase IV (DPP-IV). Investigators working with cell cultures or tissue homogenates often incorporate specific peptidase inhibitors to preserve VIP integrity during assay incubations.
Does PX1 Research ship VIP peptides internationally or domestic only?
PX1 Research provides rapid same-day fulfillment (Monday through Friday) for laboratory orders across the United States from our centralized California and Arizona distribution facilities.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.